SinoFresh Broadens Research Collaboration with Lovelace Respiratory Research Institute; Announces Additional Studies to Assess Anti-Viral Properties of Breakthrough Nasal Spray.ENGLEWOOD, Fla. -- SinoFresh HealthCare, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB: SFSH) today announced a broadening of its research collaboration with the Lovelace Respiratory Research Institute and its intent to embark on mammalian-based studies of the anti-infective properties of its lead product, SinoFresh(TM) Nasal, Oral & Sinus Care. Both announcements are being prompted by preliminary in vitro study results demonstrating strong evidence that SinoFresh's breakthrough antiseptic nasal spray can reduce the infectivity of common respiratory viruses including adenovirus adenovirus Any of a group of spheroidal viruses, made up of DNA wrapped in a protein coat, that cause sore throat and fever in humans, hepatitis in dogs, and several diseases in fowl, mice, cattle, pigs, and monkeys. and respiratory syncytial virus respiratory syncytial virus (sĭnsĭsh`əl): see cold, common. (RSV RSV respiratory syncytial virus; Rous sarcoma virus. RSV abbr. respiratory syncytial virus RSV 1 Respiratory syncytial virus, see there 2 Rous sarcoma virus, see there ). SinoFresh and the Lovelace Respiratory Research Institute (LRRI LRRI Lovelace Respiratory Research Institute ) of Albuquerque, NM first announced their formal collaboration in May of 2004. Since then, LRRI has performed a series of in vitro studies designed to assess the virucidal properties of SinoFresh(TM). Viruses are widely recognized as the most frequent cause of acute respiratory infections and are a leading cause of child mortality worldwide. SinoFresh Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Charles Fust said, "There are currently very few efficacious and commercially viable therapies in the fight against airborne viral infections. Our work with Lovelace could one day solve that problem and make a huge impact on human health." Robert Rubin, PhD., President and CEO of LRRI stated, "The results we've seen to date with SinoFresh(TM) are very encouraging and gave us the confidence and enthusiasm to move forward with more rigorous in vitro studies that more closely mimic the human respiratory system. The viruses examined in the SinoFresh studies, adenovirus and RSV, are two of the most prevalent viruses associated with respiratory infections in people." Future research will seek to expand the Company's already extensive knowledge base of the safety of its active ingredient, cetylpyridinium chloride (CPC (1) (Central Processing Complex) An IBM mainframe that has two or more central processors (CPs) that share memory. It is the collection of processors, memory and I/O subsystems manufactured with a single serial number, typically all contained in one cabinet. ), by conducting multiple studies in animal species. Additionally, LRRI is assisting in the development of a protocol intended to study the virucidal efficacy of SinoFresh(TM) and CPC in vivo. These studies are being conducted to build a research portfolio that will enable the Company to pursue a new drug application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) through the United States Food & Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). About SinoFresh HealthCare, Inc. SinoFresh HealthCare, Inc. is a developer and marketer of innovative therapies to treat inflammatory and infectious diseases of the upper respiratory system. The Company is researching broad-spectrum antiseptic approaches to reducing viral, bacterial, and fungal organisms that are suspected to cause pathogenesis of the mouth, nose, and throat. The Company holds many patents and patent applications on its innovative pharmaceutical technology and relies upon a distinguished panel of medical experts and a management team experienced in the bio-pharmaceutical arena. The Company's lead product, SinoFresh(TM) Nasal, Oral & Sinus Care, is the first over-the-counter antiseptic nasal spray that kills bacteria and molds in the nose and mouth. The Company's second product, SinoFresh(TM) Daily Antiseptic Throat Spray, will launch in the summer of 2005. The Company is also researching how antiseptic cleansing may aid in alleviating sinus distress, a problem that may affect 37 million Americans annually. SinoFresh(TM) Nasal, Oral & Sinus Care is available nationwide in Wal-Mart, Walgreens, Rite Aid, CVS (1) (Concurrent Versions System) A version control system for Unix that was initially developed as a series of shell scripts in the mid-1980s. CVS maintains the changes between one source code version and another and stores all the changes in one file. , Sav-on drugs, Osco Drug and other drug, grocery and mass merchandise retailers. More information is available at www.sinofresh.com. About The Lovelace Respiratory Research Institute Lovelace Respiratory Research Institute, located in Albuquerque, New Mexico “Albuquerque” redirects here. For other uses, see Albuquerque (disambiguation). Albuquerque (pronounced [ˈæl.bə.kɚ.kiː], Spanish: [al.βu. , is a not-for-profit research institution founded in 1947 by Dr. William Randolph Lovelace II William Randolph "Randy" Lovelace II (December 30, 1907–December 12, 1965) was an American physician who made contributions to aerospace medicine. He studied medicine at the Harvard Medical School and graduated in 1934. . It is one of the nation's largest independent basic science research institutions and the only one focused solely on respiratory health. Scientists at LRRI are committed to eradicating respiratory diseases through research aimed at understanding their causes and biological mechanisms, eliminating exposures to causal agents, and developing more effective treatments. More information is available at www.lrri.org. Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements speak only as of the date on which such statements are made and involve risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission, including risks summarized in the Company's Annual Report on Form 10-KSB for its fiscal year ended December 31, 2004 (file No. 0-49764). The Company's actual results could differ materially from such forward-looking statements. The Company undertakes no obligation to update any forward-looking statement or statements to reflect new events or circumstances or future developments. *SinoFresh(TM) is a trademark of SinoFresh HealthCare, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion